👏 Warm congratulations from IOB to Katherine A. High, Jean Bennett & Albert Maguire on the 2026 Breakthrough Prize in Life Sciences!
Katherine High, CEO of our first spin-off, RhyGaze, brings scientific rigor together with a clear focus on delivering therapies for vision loss to patients.
We are pleased to celebrate this well-deserved recognition!
🔗 More details: breakthroughprize.org/Laurea…
The work could help to explain why the risk of developing some brain conditions — such as schizophrenia and Alzheimer’s disease — differs between males and females
go.nature.com/486ipEn
The mitochondrion-targeting tool MitoCatch brings mitochondria into specific cell types through cell-surface-targeted binders. #NBThighlightnature.com/articles/s41586-0…
💡What if we could reboot sick cells?
IOB scientists @AyupovTemurkhan, @v_moreno_juan and collaborators led by @IOB_Roska have developed #MitoCatch, a system that delivers healthy mitochondria directly to diseased cells. A step toward precision mitochondrial medicine.
🧵👇
⚡ Mitochondria power our cells.
When they fail, diseases like optic nerve degeneration, Parkinson’s, or heart failure can follow. Getting healthy mitochondria to the right cells has been a major challenge.
🔬 #MitoCatch uses engineered protein binders, like a cellular GPS, to guide mitochondria exactly where they are needed. Three complementary versions of #MitoCatch enable targeted delivery.
👁️ What keeps vision cells alive?
A new study just published in Neuron (@StefanESpirig, @AlvaroHerrero1 et al.) screened 2,700 compounds across 20,000 lab grown human retinas to find out.
🧵👇
🤖As deepfakes rise, a chip could bring back trust
A new sensor technology secures images, videos, and data at capture, making manipulation detectable.
🧵👇
🧪Developed by: @FelixFranke7 (IOB), Fernando Cardes García from Andreas Hierlemann’s lab @ETH_en, financially supported by the Swiss National Science Foundation (SNSF) and the State Secretariat for Education, Research and Innovation (SERI) through the SwissChips initiative.